Gene regulation involves activation of RNA polymerase II (Pol II) that is paused and bound by the protein complexes DRB sensitivity-inducing factor (DSIF) and negative elongation factor (NELF). Here we show that formation of an activated Pol II elongation complex in vitro requires the kinase function of the positive transcription elongation factor b (P-TEFb) and the elongation factors PAF1 complex (PAF) and SPT6. The cryo-EM structure of an activated elongation complex of Sus scrofa Pol II and Homo sapiens DSIF, PAF and SPT6 was determined at 3.1 Å resolution and compared to the structure of the paused elongation complex formed by Pol II, DSIF and NELF. PAF displaces NELF from the Pol II funnel for pause release. P-TEFb phosphorylates the Pol II linker to the C-terminal domain. SPT6 binds to the phosphorylated C-terminaldomain linker and opens the RNA clamp formed by DSIF. These results provide the molecular basis for Pol II pause release and elongation activation.
. The recently solved structure of the mammalian Pol II-DSIF elongation complex showed that DSIF forms clamps around upstream DNA and exiting RNA 4 . Similar results were obtained for a related yeast complex 5 . In our accompanying paper 6 we report the structure of the paused Pol II-DSIF-NELF elongation complex (PEC), which shows that NELF binds the polymerase funnel and the open trigger loop, an element of the Pol II active site that closes to stimulate nucleotide addition. The PEC structure adopts an inactive state with a tilted DNA-RNA hybrid that impairs binding of the next nucleoside triphosphate (NTP) substrate. These results suggest possible mechanisms for NELF-stabilized Pol II pausing, but the molecular basis of pause release and formation of an activated elongation complex are not known.
The release of paused Pol II into elongation requires the positive transcription elongation factor b (P-TEFb), which comprises the kinase CDK9 and the predominant cyclin, T1 7, 8 . P-TEFb phosphorylates DSIF, NELF and the C-terminal domain (CTD) of the large Pol II subunit RPB1 [9] [10] [11] [12] [13] . The elongation factor PAF1 complex (PAF) was recently implicated in Pol II pausing and pause release 14, 15 , although its role is not clear. PAF contains the subunits PAF1, LEO1, CTR9, CDC73 and WDR61 [16] [17] [18] and is required for transcription elongation through chromatin 19, 20 . SPT6 is another conserved elongation factor that is also required for chromatin transcription 21, 22 . SPT6 stimulates transcription elongation in vitro 23 and in vivo 21 . Here we demonstrate that P-TEFb kinase activity enables the formation of a stable complex of the Pol II-DSIF elongation complex with PAF and SPT6 in vitro. We determined the cryo-EM structure of the resulting 20-subunit activated Pol II-DSIF-PAF-SPT6 elongation complex, which we call EC*. Comparison of the EC* structure with the accompanying structure 6 of the PEC elucidates how NELF is displaced for Pol II release from pausing, and how Pol II is activated for productive RNA elongation and chromatin passage.
Formation of activated elongation complex EC*
In the accompanying paper 6 , we used an RNA extension assay to recapitulate the stabilising function of NELF in the pausing of a Pol II-DSIF elongation complex in vitro 6 . To understand how Pol II is released from pause sites, we extended this assay and additionally purified recombinant human P-TEFb, a catalytically inactive P-TEFb mutant (CDK9(D149N), hereafter referred to as P-TEFb(D149N)), PAF and SPT6 (Methods, Extended Data Fig. 1a -e, Extended Data Table 1 ). Elongation complexes were formed on a DNA-RNA scaffold (hereafter denoted the modified pause scaffold, Extended Data Fig. 1b ) that enabled Pol II pausing after the addition of CTP and GTP, and enabled the use of ATP solely as a kinase substrate. Incubation of the PEC with active P-TEFb and ATP (Extended Data Fig. 1f, g ) had no effect on pausing, as previously observed 24 . However, when PAF was also included, RNA extension beyond the pause site was facilitated (Extended Data Fig. 1h, i) . When both PAF and SPT6 were included, RNA extension was strongly stimulated (Extended Data Fig. 1j, k) . These results show that PAF can reverse NELF-stabilized Pol II pausing in vitro when active P-TEFb and ATP are present, and that elongation is further stimulated when SPT6 is also present.
We then carried out RNA extension assays in the absence of NELF. When DSIF, PAF, SPT6, P-TEFb and ATP were added to the Pol II elongation complex, RNA extension was stimulated in a time-and concentration-dependent manner (Fig. 1a, Extended Data Fig. 2a-c) . Stimulation was not observed when the mutant P-TEFb(D149N) was used (Fig. 1a, Extended Data Fig. 2a-c) . When DSIF was absent, PAF and SPT6 stimulated elongation only modestly when incubated with active P-TEFb and ATP, whereas incubation with PAF or SPT6 alone had no effect (Extended Data Fig. 2d , e). This indicates that there is a functional interaction between PAF and SPT6, which is consistent with previous observations [25] [26] [27] . These results demonstrate that stimulated RNA extension in vitro requires the presence of DSIF, PAF, SPT6, active P-TEFb and ATP.
On the basis of these functional results, we used size-exclusion chromato graphy to assess whether we could form a stable, activated Pol II elongation complex in vitro (Fig. 1b , Methods, Extended Data Fig. 2f-j) . To enable subsequent structure determination, we used a nucleic acid
Structure of the activated elongation complex EC*
After purification of EC* by size exclusion chromatography and mild crosslinking with glutaraldehyde, we determined its cryo-EM structure at a nominal resolution of 3.1 Å ( Table 2 ) and resulted in a 3D reconstruction from 374,964 particles. The core of Pol II was resolved at 2.6 Å. Elongation factors were resolved at lower resolutions (around 12 Å for the most flexible domains), and their corresponding densities were improved by focused classification and refinement (Extended Data Figs. 3-5, Methods). This led to a total of eight cryo-EM density maps that enabled us to fit available structures and homology models (Extended Data Table 2) .
To complete the structure of the EC*, we determined the crystal structure of the isolated human SPT6 tandem SH2 (tSH2) domain at 1.8 Å resolution, and unambiguously docked this new structure into the corresponding density of EC* (Fig. 3 , Methods, Extended Data Figs. 5f, 6f, 7, Extended Data Table 3 ). The resulting structure of EC* shows good stereochemistry and lacks only mobile regions, including the terminal regions of PAF1 and LEO1, most of CDC73, the acidic N-terminal region of SPT6, and the C-terminal extensions of SPT5, SPT6 and CTR9 (Supplementary Table 1 ).
PAF and SPT6 structure and contacts
DSIF, PAF and SPT6 are modular proteins that coat the outer surface of Pol II (Fig. 2) . DSIF domains are arrayed around the Pol II cleft and the RNA exit tunnel 4 . PAF extends along the RPB2 side and docks on the Pol II funnel. PAF is anchored to the external domains of RPB2 by its PAF1-LEO1 dimerization module (Fig. 2b, c) . The central PAF subunit CTR9 contains 19 tetratricopeptide repeats (TPRs; residues 41-750) that each form two antiparallel α-helices (Fig. 3a , Supplementary Table 6, Extended Data Fig. 5b ). The CTR9 TPRs form a right-handed superhelix that extends from the Pol II subunit RPB11 along RPB8 via the polymerase funnel to the foot (Fig. 3a) . The TPRs are followed by a pair of helices that create a 'vertex' and connect to a prominent 'trestle' helix in CTR9 (CTR9 residues 807-892) (Extended Data Fig. 5c ). The trestle extends approximately 100 Å from the Pol II foot to subunit RPB5, where downstream DNA enters the Pol II cleft. The vertex and TPRs 13, 14 and 18 buttress the PAF subunit WDR61, which forms a seven-bladed β-propeller 28 and faces away from Pol II (Fig. 3a, Extended Data Figs. 5d, 8a ). CDC73 is mobile except for an 'anchor helix' that binds CTR9 TPR 17 (Fig. 2d) .
SPT6 binds the RPB4-RPB7 stalk on the RPB1 side of Pol II (Fig. 2c) . The SPT6 core region is well resolved and resembles the structure of the yeast SPT6 core 29 (Fig. 3b , Extended Data Fig. 5g , Supplementary Table 7) . Binding of the SPT6 core to the RPB4-RPB7 stalk includes an electrostatic interaction with the RPB7 β-strands C1-C3 (Extended Data Fig. 8b, c) . These interactions of an elongation factor with RPB4-RPB7 befit a role of the RPB4-RPB7 stalk not only during transcription initiation 30 but also during elongation 31, 32 . The SPT6 tSH2 domain is tethered flexibly to the SPT6 core and docks to Pol II at the site at which the CTD linker emerges to connect the CTD to the RPB1 body (CTD linker) (Fig. 2b) .
Interactions are also observed between the elongation factors. The SPT5 domain KOWx-KOW4 contacts the SPT6 core, which explains the known SPT5-SPT6 genetic interaction 33 and a weak physical interaction between DSIF and SPT6 23, 34 . Low-pass filtering of the cryo-EM maps also revealed a density extending C-terminally from the SPT6 tSH2 domain to the CTR9 vertex and TPRs 18 and 19 (Extended Data  Fig. 7e ). This is consistent with known interactions between SPT6 and CTR9 [25] [26] [27] . Cryo-EM density and crosslinking data further indicate that the C-terminal tail of LEO1 contacts the upstream DNA and extends to the DNA clamp formed by the SPT5 NGN and KOW1 domains (Extended Data Figs. 5e, 6e), which explains previously reported PAF-DSIF interactions [35] [36] [37] [38] [39] . Finally, initiation factors and elongation factors utilize similar regions of the Pol II surface for binding. The initiation factors TFIIB and TFIIE occupy similar regions to DSIF, whereas TFIIF and the coactivator complex Mediator engage regions bound by PAF and SPT6, respectively (Extended Data Fig. 8d ). Taken together, these results show that DSIF, SPT6 and PAF are interconnected, coat a considerable portion of the Pol II surface, and could block the reassociation of initiation factors.
Release of NELF and paused Pol II
Comparison of the EC* structure with that of the PEC reported in the accompanying paper 6 indicates that binding of NELF and PAF to Pol II is mutually exclusive (Fig. 2e, Supplementary Video 2) . In particular, Fig. 1b) . Wild-type (WT) P-TEFb (left) or the inactive mutant P-TEFb(D149N) (right) (100 nM) and 1 mM ATP were added 15 min before transcription was initiated by the addition of 10 µM GTP and CTP. Reactions were quenched at various times as indicated. Experiments were performed three times. b, Formation of the EC*. The Pol II-DSIF elongation complex assembled on the EC* scaffold was incubated with PAF and SPT6, either in the presence (+) or in the absence (−) of P-TEFb and ATP, and the resulting complexes were separated by size-exclusion chromatography (dashed lines). Dashed vertical lines mark the elution peaks of the free factors. Experiments were performed three times. c, Schematic showing conversion of the paused Pol II-DSIF-NELF elongation complex (PEC) to the activated Pol II-DSIF-PAF-SPT6 elongation complex (EC*).
Article reSeArcH
NELF association with RPB8, the foot, and the protrusion is sterically incompatible with the binding of PAF to Pol II. To test whether NELF and PAF bind Pol II in a mutually exclusive manner, we incubated the Pol II elongation complex with DSIF, NELF, PAF, P-TEFb and ATP. Under these conditions, a stable Pol II-DSIF-PAF elongation complex was formed, and NELF was excluded (Extended Data Fig. 2k, l) . Alternatively, when P-TEFb and ATP were omitted, a stable PEC was formed and PAF was excluded (Extended Data Fig. 2k, m) . These data show that P-TEFb phosphorylation enables NELF release and PAF binding in our defined biochemical system. Together with our structural data, our results further indicate that PAF prevents the reassociation of NELF with the Pol II funnel.
Comparison of the PEC and EC* structures further shows a critical difference in the conformation of the DNA-RNA hybrid. The PEC adopts an inactive conformation with a tilted DNA-RNA hybrid that impairs the binding of the NTP substrate 6 , whereas the EC* adopts the active, post-translocated conformation with a free NTP-binding site (Fig. 3c) . The trigger loop is observed in an open conformation in both the PEC and EC*. By contrast, NELF contacts the trigger loop, whereas PAF does not. The trigger loop in the EC* is therefore predicted to close easily after NTP binding, to stimulate the incorporation of nucleotides and elongation of the RNA chain. These observations explain how NELF is displaced when Pol II is released from a pause site, and how the pause-stabilizing effects of NELF are overcome in EC*.
Changes in the DSIF DNA-RNA clamp
Our biochemical data show that PAF and SPT6 stimulate RNA extension (Fig. 1a, Extended Data Fig. 2a, d , e), consistent with published results of a stimulatory role of SPT6 in vitro 23 and in vivo 21 . Because neither PAF nor SPT6 reach the Pol II active site, the stimulatory effect is allosteric in nature. Comparison of the EC* structure with structures of the Pol II-DSIF elongation complex 4 and the PEC 6 revealed several conformational changes on the Pol II surface (Fig. 4a , Supplementary Video 3) that can explain the stimulatory effect of SPT6. The changes include repositioning of the RPB4-RPB7 stalk (Fig. 4b) and rearrangement of the SPT5 domains KOW2-KOW3 and KOWx-KOW4 (Fig. 4c) . KOWx-KOW4 is rotated by 50° and moves away from exiting RNA by approximately 12 Å. This rearrangement breaks the previously observed contacts of the KOWx-KOW4 linker with RNA 4 , and thereby opens the RNA clamp of DSIF (Fig. 4c) .
The rearrangement of KOW2-KOW3 and KOWx-KOW4 disrupts their previously observed interaction with KOW1 in the Pol II-DSIF , which results in a 40° rotation of KOW1 away from the upstream DNA. The rotation is accompanied by a movement of the upstream DNA, which is bent away from the protrusion (Fig. 4d ). This generates a space between the upstream DNA and the protrusion that is occupied by the LEO1 C-terminal extension (Fig. 4e, Extended Data Fig. 5e ). The path of the LEO1 extension is similar to that of a linker in the small subunit of the initiation factor TFIIF 40 . LEO1 may thereby stabilize the upstream DNA and KOW1 in a new position that could facilitate the rewinding of upstream DNA. DNA rewinding is beneficial for elongation and is facilitated by the SPT5 homologue NusG in the bacterial system 41 . SPT4 and the SPT5 NGN domain remain fixed to keep the Pol II cleft closed and retain nucleic acids. Taken together, these findings show that PAF and SPT6 alter the DSIF DNA and RNA clamps, respectively, and stabilize the EC* conformation to stimulate elongation activity.
How P-TEFb triggers EC* formation
To investigate how P-TEFb triggers conversion of the PEC to EC*, we determined P-TEFb phosphorylation sites in vitro (Extended Data Table 5 ). We confirmed that P-TEFb phosphorylates the Pol II CTD and also mapped phosphorylation sites on DSIF, NELF, PAF and SPT6. We obtained 49 phosphorylation sites, of which ten per cent are known P-TEFb sites 10, 12, 42 . Most of the phosphorylation sites are found in databases (Methods), which demonstrates that they are present in vivo. P-TEFb phosphorylates the NELF-A 'tentacle' , which binds Pol II and is required for NELF-stabilized pausing 6, 43 . Phosphorylation of the NELF-A tentacle may facilitate NELF dissociation 42 . Phosphorylation of the SPT5 linker that connects KOWx-KOW4 and KOW5 may help to open the DSIF RNA clamp 12 .
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We next considered how P-TEFb enables the recruitment of SPT6. The SPT6 tSH2 domain lies adjacent to the CTD linker (Fig. 2b) . It was recently reported that the yeast tSH2 domain binds to the phosphorylated CTD linker 44 . We therefore tested whether the human CTD linker can be phosphorylated by P-TEFb. Indeed, P-TEFb could phosphorylate six human CTD linker residues in vitro (Extended Data Fig. 10a -f, Methods), of which Thr1525 corresponds to the yeast site Thr1471
44
. Furthermore, a P-TEFb-treated CTD linker peptide bound the human tSH2 domain (Fig. 5a , Methods). We also found that the tSH2 domain is required for binding a linker-containing CTD variant, for SPT6 incorporation into EC*, and for the stimulation of elongation (Extended Data Fig. 10g -j), in accordance with previous work 45, 46 . Finally, modelling shows that the phosphorylated CTD linker can meander along a positively charged crevice of the human tSH2 domain (Fig. 5b , Extended Data Fig. 7f ). These results show that P-TEFb phosphorylates the human CTD linker, and this enables SPT6 tSH2 binding and the stable docking of SPT6 to Pol II.
Binding of the CTD linker to SPT6 brings the CTD closer to the Pol II surface and the exiting RNA transcript. The exiting RNA in EC* passes through a positively charged groove formed between the S1 and the RuvC-like domains of the SPT6 core (Fig. 5c ). Consistent with this structural observation, SPT6 modestly binds single-stranded nucleic acids (Extended Data Fig. 10k ), and yeast SPT6 crosslinks to nascent RNA in cells 47 . Factors involved in co-transcriptional RNA processing associate with the phosphorylated CTD, but also with the CTR of SPT5 11 . The CTR is also phosphorylated by P-TEFb 11, 13 and extends from the KOW5 domain that lies adjacent to the exiting RNA. These findings reveal that the structural features involved in co-transcriptional RNA processing are clustered on the EC* surface (Extended Data  Fig. 8e ). The biochemical definition and structural characterization of EC* therefore provides a starting point for the analysis of elongationcoupled events such as co-transcriptional pre-mRNA processing.
Discussion
We report here that Pol II release from the paused state and elongation activation requires P-TEFb, PAF and SPT6 in vitro. We solved the structure of the activated Pol II-DSIF-PAF-SPT6 elongation complex, which we call EC*. Together with the accompanying paper 6 , our work provides the molecular basis for Pol II pausing, release of Pol II from the paused state, and elongation activation. It also establishes a molecular framework for a detailed analysis of promoter-proximal transcriptional gene regulation by P-TEFb.
Comparison of the EC* structure with the PEC structure 6 provides a model for understanding how paused Pol II is released into elongation and how elongation is activated (Fig. 6a) . PAF sterically competes with NELF for binding to the Pol II funnel, and P-TEFb phosphorylation influences competition between NELF and PAF to facilitate NELF release and PAF binding. This is consistent with a requirement of PAF for pause release in cells 14 . P-TEFb phosphorylates not only the Pol II CTD, DSIF, NELF, PAF and SPT6, but also targets the CTD linker, to promote SPT6 binding. Interactions of PAF and SPT6 induce conformational changes in the DSIF clamps on upstream DNA and exiting RNA, respectively. These changes may promote DNA rewinding at the upstream edge of the transcription bubble, to drive the polymerase forward 48 , and may facilitate RNA passage through the exit tunnel, to further stimulate elongation.
Finally, PAF and SPT6 have important roles in enabling transcription of the natural template, chromatin 19, 20 . Yeast PAF binds the major histone H3K4 methyltransferase Set1
49
. PAF could reach downstream nucleosomes via its long trestle helix, and this may facilitate histone methylation by SET1 when Pol II approaches a nucleosome. SPT6 is a histone chaperone, and its N-terminal region binds to histones and the nucleosome-interacting protein IWS1 45, 46, 50 . Although this SPT6 region is mobile in our structure, its location is constrained to the area between upstream and downstream DNA. This is consistent with the idea that SPT6 stores histones while Pol II transcribes through a nucleosome, thereby avoiding loss of histones and retaining epigenetic information during Pol II passage (Fig. 6b) . Therefore, the EC* structure provides a starting point for analysing the mechanisms of chromatin transcription.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0440-4. and DSIF and EC* subunits are coloured as in Fig. 2a. b . CTR9 was cloned with a C-terminal tobacco etch virus (TEV) protease cleavable 6× His tag. All subunits were incorporated into a single plasmid by successive rounds of ligation-independent cloning. A cDNA clone encoding fulllength human SPT6 (1-1726) (Harvard Plasmid Repository) was used as a PCR template for insertion of SPT6 into the 438-C vector (Addgene, 55220), which bears an N-terminal His6-MBP-tag (MBP, maltose-binding protein) followed by a TEV protease site. SPT6 ∆tSH2 (1-1297) was cloned by round-the-horn site-directed mutagenesis. The SPT6 tSH2 (1323-520) was amplified from cDNA and cloned into the 438-C vector.
A baculovirus expression plasmid encoding P-TEFb (CDK9 1-372, CYCT1 1-272) (pACEBac1, Geneva Biotech) was a gift from M. Geyer (University of Bonn). CDK9 is tagged with an N-terminal His8 tag followed by a TEV protease cleavage site. CYCT1 is tagged N-terminally with a GST tag followed by a TEV protease cleavage site. The CDK9 mutation Asp149Asn was introduced by sitedirected mutagenesis.
Bacmid, virus and protein production for PAF, SPT6 and P-TEFb were performed as previously described 52 . Sf9 (ThermoFisher), Sf21 (Expression Systems) and Hi5 (Expression Systems) cell lines were not tested for mycoplasma contamination and were not authenticated in-house. Hi5 cells expressing PAF or SPT6 or P-TEFb were collected by centrifugation, resuspended in lysis buffer (300 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol, 30 mM imidazole, 1 mM dithiothreitol (DTT), 0.284 µg ml −1 leupeptin, 1.37 µg ml −1 pepstatin A, 0.17 mg ml −1 PMSF and 0.33 mg ml −1 benzamidine), flash-frozen and stored at −80 °C until purification.
Regions of human RPB1 corresponding to the linker and CTD (1488-1970, 1593-1970, 1488-1592) were amplified from an RPB1 cDNA clone and inserted into a modified pET24b vector with an N-terminal His6-MBP tag followed by a TEV site (Addgene, 29654, 1C vector) by ligation-independent cloning. The 1593-1970 variant was also cloned into a modified pGEX vector as previously described 47 . RPB1 CTD variants were overexpressed in Escherichia coli BL21(DE3) RIL cells grown in LB medium. Cells were grown at 37 °C and protein expression was induced with 0.5 mM isopropyl β-d-1-thiogalactopyranoside when cells reached an optical density at 600 nm (OD 600 ) of around 0.5. Cells were collected after 3 h by centrifugation, resuspended in lysis buffer, flash-frozen and stored at -80 °C. Protein purification. All steps were performed at 4 °C unless otherwise stated. Pol II, DSIF, NELF and TFIIS were purified as described in the accompanying paper 6 . PAF was purified from 2-4 l of Hi5 expression. Cell pellets were lysed by sonication and cleared by centrifugation. Clarified lysate was filtered through 0.8 µm syringe filters and applied to a 5 ml HisTrap HP column (GE Healthcare Life Sciences) equilibrated in lysis 400 buffer (400 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol, 30 mM imidazole pH 8.0, 1 mM DTT, 0.284 µg ml −1 leupeptin, 1.37 µg ml −1 pepstatin A, 0.17 mg ml −1 PMSF and 0.33 mg ml −1 benzamidine). The column was washed with ten column volumes of lysis 400 buffer, followed by three column volumes of lysis 800 buffer (800 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol, 30 mM imidazole pH 8.0, 1 mM DTT, 0.284 µg ml −1 leupeptin, 1.37 µg ml −1 pepstatin A, 0.17 mg ml −1 PMSF and 0.33 mg ml −1 benzamidine) and three column volumes of lysis 400 buffer. The column was then equilibrated in low-salt buffer (150 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol, 30 mM imidazole pH 8.0, 1 mM DTT, 0.284 µg ml −1 leupeptin, 1.37 µg ml −1 pepstatin A, 0.17 mg ml −1 PMSF and 0.33 mg ml −1 benzamidine). A HiTrap Q column equilibrated in low-salt buffer (5 ml, GE Healthcare Life Sciences) was attached to the base of the HisTrap column. The nickel column was developed over a gradient with Nickel 150 elution buffer (150 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol, 500 mM imidazole pH 8.0, 1 mM DTT, 0.284 µg ml −1 leupeptin, 1.37 µg ml −1 pepstatin A, 0.17 mg ml −1 PMSF and 0.33 mg ml −1 benzamidine). The HisTrap column was then removed, and the HiTrap Q was washed with five column volumes of low-salt buffer. The HiTrap Q column was then developed over a gradient into lysis 800 buffer. Peak fractions were assessed by SDS-PAGE and Coomassie staining. Fractions containing PAF were pooled and mixed with TEV protease 53 and lambda protein phosphatase. The protein was placed in a Slide-A-Lyzer 10 kDa molecular weight cutoff (MWCO) (ThermoFisher Scientific) and dialysed overnight against lysis buffer 400 containing 1 mM MnCl 2 . The protein was then applied to a 5 ml HisTrap column equilibrated in lysis buffer 400 to remove uncleaved protein, the His tag and TEV protease. The flow-through was collected and concentrated in 100 kDa MWCO Amicon Ultra Centrifugal Filters (Merck). The protein was then applied to a HiLoad S200 16/600 pg column equilibrated in SE buffer (300 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol and 1 mM DTT). Peak fractions were assessed by SDS-PAGE and Coomassie staining. Pure peak fractions containing PAF were pooled and concentrated in a 100 kDa MWCO Amicon Ultra Centrifugal Filters (Merck), aliquoted, snap frozen and stored at −80 °C until use. The identity of individual subunits was confirmed by mass spectrometric analysis.
Wild-type SPT6, SPT6∆tSH2 and the SPT6 tSH2 were purified from 1.2 l of Hi5 cells. Cell pellets were lysed by sonication and cleared by centrifugation. Clarified lysate was filtered through 0.8 µm syringe filters and applied to a 5 ml HisTrap HP column (GE Healthcare Life Sciences) equilibrated in lysis buffer. The column was washed with five column volumes of lysis buffer followed by two column volumes of high-salt 1000 buffer (1,000 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol, 30 mM imidazole pH 8.0, 1 mM DTT, 0.284 µg ml −1 leupeptin, 1.37 µg ml −1 pepstatin A, 0.17 mg ml −1 PMSF and 0.33 mg ml −1 benzamidine) and two column volumes of lysis buffer. The HisTrap column was then attached to a 15 ml amylose column equilibrated in lysis buffer (New England Biolabs), packed in an XK column (GE Healthcare Life Sciences). Protein was eluted from the HisTrap column directly onto the amylose column in nickel elution buffer (300 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol, 500 mM imidazole pH 8.0, 1 mM DTT, 0.284 µg ml −1 leupeptin, 1.37 µg ml −1 pepstatin A, 0.17 mg ml −1 PMSF and 0.33 mg ml −1 benzamidine). After five column volumes, the HisTrap column was removed and the amylose column was washed with two column volumes of highsalt 1000 buffer followed by two column volumes of lysis buffer. The protein was eluted from the amylose column in amylose elution buffer (300 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol, 117 mM maltose, 1 mM DTT, 0.284 µg ml −1 leupeptin, 1.37 µg ml −1 pepstatin A, 0.17 mg ml −1 PMSF and 0.33 mg ml −1 benzamidine). Peak fractions were assessed on SDS-PAGE and Coomassie staining. Peak fractions corresponding to full-length SPT6 were pooled, mixed with TEV protease and lambda protein phosphatase, and dialysed against lysis buffer with 1 mM MnCl 2 overnight in a 10 kDa MWCO Slide-A-Lyzer. The protein was then applied to a HisTrap column equilibrated in lysis buffer to remove the uncleaved protein, the His6-MBP tag and TEV protease. The flow-through was collected, concentrated in a 100 kDa MWCO Amicon Ultra Centrifugal Filter (Merck), and applied to a HiLoad S200 16/600 pg column equilibrated in SE buffer. Peak fractions were assessed by SDS-PAGE and Coomassie staining. Pure peak fractions containing SPT6 were pooled and concentrated in a 100 kDa MWCO Amicon Ultra Centrifugal Filters (Merck), aliquoted, flash-frozen and stored at −80 °C until use. The tSH2 was purified in essentially the same way with the exception that the protein was not subjected to amylose purification. Wild-type P-TEFb and D149N P-TEFb were purified from 4 l of Hi5 expression. Cell pellets were thawed, lysed by sonication and cleared by centrifugation. Clarified lysate was filtered through 0.8 µm syringe filters and applied to a 5 ml HisTrap HP column (GE Healthcare Life Sciences) equilibrated in lysis buffer. The column was washed with five column volumes of lysis buffer followed by two column volumes of high-salt 1000 buffer and two column volumes of lysis buffer. The column was then washed with five column volumes of low salt buffer and connected to a HiTrap S column (GE Healthcare Life Sciences) equilibrated in low salt buffer. The HisTrap was developed with a gradient of Nickel 150 elution buffer. The flow-through was collected and peak fractions were analysed by SDS-PAGE followed by Coomassie staining. Peak fractions containing P-TEFb were pooled and mixed with TEV protease. The protein was dialysed against lysis buffer overnight in a 10 kDa MWCO Slide-A-Lyzer. The protein was removed from the Slide-A-Lyzer and applied to a HisTrap column equilibrated in lysis buffer. The flow through was collected and concentrated in a 10 kDa MWCO Amicon Ultra Centrifugal Filters (Merck) and applied to a HiLoad S200 16/600 pg column equilibrated in SE buffer. Peak fractions were assessed by SDS-PAGE and Coomassie staining. Pure peak fractions containing P-TEFb were pooled and concentrated in a 10 kDa MWCO Amicon Ultra Centrifugal Filters (Merck) to a final concentration of 5-10 µM, aliquoted, snap frozen, and stored at −80 °C until use.
His6-MBP RPB1 constructs (1488-1592, 1488-1970 and 1593-1970) were purified using a similar scheme. Cell pellets were thawed, lysed by sonication, and cleared by centrifugation. Lysates were filtered through 0.8 µm syringe filters and applied to 5 ml HisTrap columns equilibrated in lysis buffer. The columns were washed with ten column volumes lysis buffer, two column volumes of high-salt 1000 buffer followed by two column volumes of lysis buffer. The proteins were eluted from the HisTrap column with Nickel elution buffer over a gradient of nine column volumes. For the 1488-1592 construct, peak fractions were pooled and concentrated in 10 kDa MWCO Amicon Ultra Centrifugal Filters (Merck) and applied to a HiLoad S75 16/600 column equilibrated in SE buffer. For the 1488-1970 and 1593-1970 constructs, the HisTrap column was attached to an Amylose column equilibrated in lysis buffer as the HisTrap column was eluted. The HisTrap Article reSeArcH column was then removed and the amylose column was washed with two column volumes of high-salt 1000 buffer followed by two column volumes of lysis buffer. The protein was eluted from the amylose column with amylose elution buffer. Peak fractions were concentrated in 30 kDa MWCO Amicon Ultra Centrifugal Filters (Merck) and applied to a HiLoad S200 16/600 pg column equilibrated in SE buffer. Peak fractions eluting from the S75 and S200 columns were assessed by SDS-PAGE followed by Coomassie staining. The protein constructs were concentrated as above, flash-frozen in liquid nitrogen and stored at −80 °C until use. RNA extension assays. Transcription assays were performed with complementary DNA scaffolds that were designed to disfavour ATP misincorporation [54] [55] [56] . All oligos were purchased from Integrated DNA Technologies, resuspended in water (100 µM), flash-frozen in liquid nitrogen and stored at −80 °C. The sequences used for transcription assays are as follows: Modified pause scaffold: template DNA 5′-CCA CAG GAA GAA CAG AAA CAA CGG GCG GAA CTA TGC CGG ACG TAC TGA CCA-3′, non-template DNA 5′-Biotin-TTT TTG GTC AGT ACG TCC GGC ATA GTT CCG CCC GTT GTT TCT GTT CTT CCT GTG G-3′, RNA 5′-/6-FAM-UUU UUU GGC AUA GUU-3′; EC* transcription scaffold: template DNA GTT TCC CCC AGC TCC CAG CTC CCT GCT GGC TCC GAG TGG GTT CTG CCG CTC TCA ATG G, non-template DNA CCA TTG AGA GCG GCA GAA CCC ACT CGG AGC CAG CAG GGA GCT GGG AGC TGG GGG AAA C, RNA 5′-/6-FAM-UUA AGG AAU UAA GUC GUG CGU CUA AUA ACC GGA GAG GGA ACC CAC U-3′. The modified pause scaffold contains 13 nucleotides of upstream DNA, 28 nucleotides of downstream DNA, a nine-base pair (bp) DNA-RNA hybrid, and six nucleotides of exiting RNA bearing a 5′ 6-FAM label (Extended Data Fig. 1 ). The modified pause scaffold was derived from the pause scaffold (bacterial) 6,56 and was altered to disfavour ATP misincorporation during incubation steps with P-TEFb 54 . The EC* transcription scaffold contains 15 nucleotides of upstream DNA, 34 nucleotides of downstream DNA, a ninebase-pair DNA-RNA hybrid, and 37 nucleotides of exiting RNA bearing a 5′ 6-FAM label. The EC* transcription scaffold has same sequence as the EC* scaffold but a matched DNA bubble and an additional ten bases of DNA at the downstream edge of the DNA. RNA extension assays performed on the EC* transcription scaffold resemble the activity observed on the modified pause scaffold (Extended Data Fig. 1l, m) .
RNA and template DNA were mixed in equimolar ratios and were annealed by incubating the nucleic acids at 95 °C for 5 min and then decreasing the temperature by 1 °C min −1 steps to a final temperature of 30 °C in a thermocycler in a buffer containing 100 mM NaCl, 20 mM Na-HEPES pH 7.4, 3 mM MgCl 2 and 10% (v/v) glycerol. All concentrations refer to the final concentrations used in the assay. S. scrofa Pol II (75 nM) and the RNA-template hybrid (50 nM) were incubated for 10 min at 30 °C, shaking at 300 rpm. The non-template DNA (50 nM) was added and the reactions were incubated for another 10 min. The reactions were then diluted to achieve final assay conditions of 100 mM NaCl, 20 mM Na-HEPES pH 7.4, 3 mM MgCl 2 , 4% (v/v) glycerol and 1 mM DTT and were again incubated for 10 min. Factors were diluted in protein dilution buffer (300 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol and 1 mM DTT) and added to Pol II elongation complexes as serial dilutions (0-750 nM) or at a concentration of 75 or 150 nM for time-course experiments. Wild-type P-TEFb or the inactive P-TEFb mutant D149N was added (100 nM) with 1 mM ATP and incubated with Pol II and the elongation factors for 15 min at 30 °C. Transcription reactions were initiated by adding GTP and CTP (10 µM) to permit elongation to position +7 (modified pause scaffold) or GTP, CTP and UTP (10 µM) (EC* transcription scaffold). Reactions were quenched after 1-2 min (titration experiments) and after (0-5 min) for time-course experiments in 2x stop buffer (6.4 M urea, 50 mM EDTA pH 8.0, 1x TBE buffer). Samples were treated with 4 µg of proteinase K for 30 min (New England Biolabs) and were separated by denaturing gel electrophoresis (8 µl of sample applied to an 8 M urea, 1x TBE, 20% Bis-Tris acrylamide 19:1 gel run in 0.5x TBE buffer at 300 V for 90 min). Products were visualized using the 6-FAM label and a Typhoon 9500 FLA Imager (GE Healthcare Life Sciences).
Gel images were quantified using ImageJ version 1.48v 57 . The integrated density of the elongated product was measured using a box size of 0.35 × 0.15 cm. All integrated density values were normalized by subtracting the background integrated density from each gel. Graphs were prepared in GraphPad Prism version 6. Each bar or point represents the mean intensity from two or three individual replicates. Error bars reflect the standard deviation between the replicates. Source data for gel quantification can be found in Supplementary Table 8 .
We observe extension from a fraction of the input RNA molecules. We attribute this to inefficient assembly of the elongation complex on the perfectly complementary scaffolds used in our assays. It was previously shown that only 10-50% of yeast Pol II molecules successfully assemble on perfectly complementary scaffolds [58] [59] [60] [61] owing to non-template DNA displacement of the RNA primer 58 . Others have resolved the problem of displaced RNA primer by incorporating radioactive NTPs or by immobilizing non-template DNA containing complexes on beads. We chose to perform RNA extension experiments in bulk with a fluorescently labelled RNA to maintain consistent Pol II concentrations across experiments and reproducibility in time-course experiments. Analytical gel filtration. Elongation complexes were formed on a bubble scaffold with the following nucleic acid sequence (EC* scaffold): template DNA 5′-GCT CCC AGC TCC CTG CTG GCT CCG AGT GGG TTC TGC CGC TCT CAA TGG-3′, non-template DNA 5′-CCA TTG AGA GCG GCC CTT GTG TTC AGG AGC CAG CAG GGA GCT GGG AGC-3′, and RNA 5′-/6-FAM -UUA AGG AAU UAA GUC GUG CGU CUA AUA ACC GGA GAG GGA ACC CAC U-3′. Pol II elongation complexes were formed as described for the transcription assays (25 pmol final Pol II, 50 pmol RNA-DNA template, 100 pmol non-template DNA). Elongation factors were added in 2-3 molar excess relative to Pol II in a final buffer containing 100 mM NaCl, 20 mM Na-HEPES pH 7.4, 3 mM MgCl 2 . 1 mM DTT, and 4% (v/v) glycerol. Reactions that included P-TEFb (18 pmol) were supplemented with 1 mM ATP pH 7.5. Reactions were incubated for 30 min at 30 °C. Samples were applied to a Superose 6 increase 3.2/300 column equilibrated in complex buffer (100 mM NaCl, 20 mM Na-HEPES pH 7.4, 4% (v/v) glycerol, 3 mM MgCl 2 and 1 mM DTT). Peak fractions were analysed by SDS-PAGE followed by Coomassie staining. Sample preparation for cryo-EM. Samples for cryo-EM were prepared essentially as described for analytical gel filtration runs. Final protein amounts used for complex formation were 112 pmol Pol II, 168 pmol RNA-template DNA hybrid, 200 pmol non-template DNA, 224 pmol PAF, DSIF and SPT6, 38 pmol P-TEFb and 313 pmol TFIIS (when included). Peak fractions corresponding to the complex were individually crosslinked with 0.1% (v/v) glutaraldehyde for 10 min on ice. Reactions were quenched with 8 mM aspartate and 2 mM lysine and were dialysed against a buffer containing 100 mM NaCl, 20 mM Na-HEPES pH 7.4, 20 mM Tris-HCl pH 7.5, 1 mM DTT and 3 mM MgCl 2 , in 20 kDa MWCO Slide-A-Lyzer MINI Dialysis Units for 6 h at 4 °C. Sample from the peak (150-175 nM) was applied to R2/2 gold grids and R2/1 carbon grids (Quantifoil). The grids were glow-discharged for 45 s before applying 2 µl of sample to each side of the grid (4 µl total). After incubation for 10 s and blotting for 8.5 s, the grid was vitrified by plunging it into liquid ethane with a Vitrobot Mark IV (FEI Company) operated at 4 °C and 100% humidity. Cryo-EM data collection and data processing. Three separate datasets were collected, two of which were collected in the presence of TFIIS. TFIIS was included because of its reported role in stabilizing the association of PAF with Pol II 19 . Here we describe the structure lacking TFIIS. Cryo-EM data was collected on a FEI Titan Krios II transmission electron microscope operated at 300 keV. A K2 summit direct detector (Gatan) with a GIF quantum energy filter (Gatan) was operated with a slit width of 20 eV. Automated data acquisition was done with FEI EPU software at a nominal magnification of 130,000×, corresponding to a pixel size of 1.049 Å per pixel. Image stacks of 40 frames were collected over 10 s in counting mode. The dose rate was 3.4-4.7 e − per Å 2 per s for a total dose of 34-47 e − per Å 2 . A total of 20,198 image stacks were collected.
Frames were stacked and subsequently processed with MotionCorr2
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. CTF correction was performed with Gctf 63 . Image processing was performed with RELION 2.1 64, 65 . Particles were auto-picked using projections of an initial reconstruction of PAF and DSIF bound to Pol II (data not shown) yielding 1,775,917 particle images. Particles were extracted using a box size of 360 2 pixels, normalized, and screened using iterative rounds of reference-free 2D classification resulting in 1,675,585 particles. Particles from each of the three datasets were initially processed separately. An initial reconstruction of Pol II bound to PAF and DSIF (not shown) was low-pass filtered to 50 Å and used for hierarchical 3D-classification with and without image alignment and 3D-refinement. Classes showing density for TFIIS were omitted. The best resolved, non-TFIIS bound classes from each dataset were selected and combined resulting in 374,964 particles (dataset 1: 101,509 particles, dataset 2 (TFIIS): 58,720 particles, dataset 3 (TFIIS): 214,745 particles). The combined particles were subjected to 3D refinement using a 50 Å low-pass-filtered map from a previous 3D-refinement resulting in a reconstruction with a resolution of 3.10 Å (map A). Some domains were not well resolved in the reconstruction, so 3D classifications without image alignment with applied soft masks around the regions of interest were performed. Masks were generated in Chimera (version 1.10.2) and RELION 2.1 around the DSIF NGN (map B, 3.10 Å), KOW1 (map C, 3.49 Å), and KOWx-KOW4 (map D, 3.20 Å) domains, the SPT6 core (map E, 3.28 Å) and SPT6 tSH2 (map F, 3.49 Å), upstream DNA (map G, 3.10 Å), and CTR9 (map H, 3.34 Å) 66 . Particles containing the desired density were subjected to global 3D refinement. To further improve densities, focused refinement was used for regions of CTR9, SPT6 and the RPB4-RPB7 stalk. Focused refinements were performed by continuing global refinements after the first iteration of local searches and applying a soft mask. Masks were generated for three regions of CTR9/WDR61 comprising the N-terminal region, middle region, and C-terminal region/WDR61 (map H). The C-terminal region/WDR61 focused refinement resulted in a final resolution of 3.59 Å with an applied B-factor of −145.94 Å 2 . Focused refinement for RPB4-RPB7 was performed using map H resulting in a final resolution Model building. The structure of EC* was solved by first placing the structure of a bovine elongation complex into map A in Chimera 66 (PDB ID: 5OIK) 4 . Adjustments were made to the protein sequence, DNA sequence, and positioning of the upstream DNA in Coot 69 . The human RPB4-RPB7 crystal structure (PDB ID: 2C35) 70 was placed into a focused refined version of map H in Chimera. Human DSIF from a previously solved cryo-EM structure (PDB ID: 5OIK) 4 was divided into five regions for modelling, corresponding to the SPT5 NGN and SPT4, KOW1, KOW2-KOW3, KOWx-KOW4 and KOW5 and placed into globally refined maps. KOW2-KOW3 and KOW5 were placed in map A by rigid-body fitting in Chimera. The NGN domain and SPT4 were placed in map B by rigid-body fitting in Chimera. KOW1 and KOWx-KOW4 were placed into map C and map D, respectively, by rigid-body fitting in phenix.real_space_refine 71 . Densities for all five PAF subunits are observed. PAF was modelled using the known crystal structure for WDR61 (PDB ID: 3OW8) and homology modelling for the remaining subunits. A model for CTR9 1-798 was generated with Robetta 72 using PDB ID 4BUJ 73 as a template. Secondary structure predictions from SABLE 74 and PSIPRED 75 were used to confirm the model. TPRs were identified and validated with TPRpred 76 . CTR9 807-892 was built de novo in Coot in a focused refined version of map H. Crosslinking restraints and densities from bulky residues such as Arg and Tyr were used as sequence markers. The Robetta model of CTR9 was divided into four parts corresponding to residues 1-303, 303-677, 678-750 and 750-798 and fit into map H or focused refined versions of map H. WDR61 was placed into a focused refined version of map H and is shown as an atomic model. The orientation was determined from crosslinking data (Extended Data Fig. 6 ). CTR9 and WDR61 were flexibility fit into focused refined versions of map H using VMD and MDFF 77 . The N terminus of CTR9 (1-300) is not well resolved, and is modelled as a backbone trace with unknown register. Clear helical densities are observed for residues 301-750 and are shown as backbone traces.
The predicted structural similarity between the triple barrel dimerization domain of TFIIF and PAF1/LEO1 was used to generate a homology model for PAF1/LEO1 78 . PAF1 (188-341) and LEO1 (367-608) were separately threaded through the RAP74 and RAP30 subunits of human TFIIF (PDB ID: 5IYC) 40 , respectively, using Phyre2 (99.05/99.81% confidence of threading). These regions were chosen owing to their predicted secondary structure similarity to TFIIF. The threaded model for LEO1 was truncated to residue 497. The threaded models for PAF1 and LEO1 were aligned on the TFIIF structure 40 and placed into the corresponding density in UCSF Chimera. Residues 498-529 of LEO1 were built de novo in Coot using crosslinking restraints and secondary structure predictions. PAF1 and LEO1 residues are modelled as backbone traces with an unknown register.
CDC73 is the least well-resolved subunit in our structure. Extensive crosslinking between CDC73 and CTR9 and noisy density near CTR9 suggests that CDC73 is highly mobile. We observe an additional helix immediately adjacent to CTR9 TPR 17 that cannot be assigned to CTR9. Crosslinking data and secondary structure predictions assigned this 'anchor helix' to CDC73 residues 249-262. This assignment is consistent with biochemical experiments that have collectively shown that a region of CDC73 corresponding to residues 200-337 is required for its association with PAF [79] [80] [81] . We compared our PAF structure with the published yeast Pol II-PAF-TFIIS structure 78 . The general Pol II binding surfaces of yeast and human PAF are shared; however, there are several notable differences between the structures. First, there is a substantial difference in subunit composition between yeast and human PAF [16] [17] [18] 82 . Yeast PAF stably associates with Rtf1 and does not associate with Ski8 (WDR61 in human), whereas the opposite is true for human PAF. Second, the yeast Ctr9 construct used for cryo-EM was severely truncated and lacked the trestle helix. The trestle helix makes additional contacts with Pol II that may confer stability. Last, the yeast structure was solved as a ternary structure with Pol II and TFIIS, which may have rendered the complex more flexible. DSIF, SPT6 and P-TEFb phosphorylation greatly stabilize human PAF association with Pol II (data not shown). Together, these differences may have contributed to the higher flexibility of the yeast structure and differences in subunit assignment.
To generate a model for SPT6, the human sequence for SPT6 was threaded through a crystal structure of the Saccharomyces cerevisiae Spt6 core region (PDB ID: 3PSI) 29 with Phyre2
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. The model generated by Phyre2 was flexibility fit into a focused refined version of map E using VMD and MDFF 77 . The model was manually adjusted in Coot. Most domains of the central region are easily resolved with the exception of the death-like domain, which is more flexible than the rest of the complex (Extended Data Fig. 4, 5) . We modelled three of a total of nine human-specific short insertions within the SPT6 core. The core was modelled as a backbone trace. The crystal structure of the human tSH2 was placed into map F using rigid-body fitting in phenix.real_space_refine. A loop corresponding to residues 1385-1395 was removed. The CTD linker was modelled using a previously solved crystal structure of yeast SPT6 tSH2 with bound CTD linker (PDB ID: 5VKO
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). The CTD linker was mutated to the corresponding human sequence with Phyre2 and fit onto the human tSH2 by matching the cores of the yeast and human tSH2 crystal structures in PyMOL (Schrödinger LLC, version 1.8.6.0).
The model was manually adjusted in Coot 69 and refined with phenix.real_ space_refine against a locally filtered, non-sharpened version of map A. The final model has 95.07% of residues in most-favoured regions of the Ramachandran plot according to MolProbity 84 . The structure has a MolProbity score of 1.64. Figures were generated in PyMOL (Schrödinger LLC, version 1.8.6.0) and UCSF Chimera (version 1.10.2). Surface charge was calculated with PDB2PQR 85 and visualized with APBS 86 in PyMOL (Schrödinger LLC, version 1.8.2.3). Crosslinking-mass spectrometry. Samples for crosslinking and mass spectrometry analysis were essentially prepared as those used for cryo-EM. Fractions containing EC* were pooled and mixed with 2 mM of BS3 dissolved in complex buffer (No Weigh Format, ThermoFisher Scientific). The protein was incubated for 30 min at 30 °C. The crosslinking reaction was quenched by adding 100 mM Tris-HCl pH 7.5 and 20 mM ammonium bicarbonate (final concentrations). The reaction was incubated for 15 min further at 30 °C. The protein was precipitated with 300 mM sodium acetate pH 5.2 and four volumes of acetone and incubated overnight at −20 °C. The protein was pelleted by centrifugation, briefly dried, and resuspended in 4 M urea and 50 mM ammonium bicarbonate.
Crosslinked proteins were reduced with 10 mM DTT for one hour at room temperature. Alkylation was performed by adding iodoacetamide to a final concentration of 40 mM, and incubating for 30 min in the dark at room temperature. After dilution to 1 M urea with 50 mM ammonium bicarbonate (pH 8.0), the crosslinked protein complex was digested with trypsin in a 1:50 enzyme-to-protein ratio at 37 °C overnight. Peptides were acidified with trifluoroacetic acid (TFA) to a final concentration of 0.5% (v/v), desalted on MicroSpin columns (Harvard Apparatus) following manufacturer's instructions and vacuum-dried. Dried peptides were dissolved in 50 µl 30% acetonitrile/0.1% TFA and peptide size exclusion (pSEC, Superdex Peptide 3.2/300 column on an ÄKTAmicro system, GE Healthcare) was performed to enrich for crosslinked peptides at a flow rate of 50 µl min −1
. Fractions of 50 µl were collected. Fractions containing the crosslinked peptides (1-1.7 ml) were vacuum-dried and dissolved in 2% acetonitrile/0.05% TFA (v/v) for analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS).
Crosslinked peptides derived from pSEC were analysed as technical duplicates on an Orbitrap Fusion and Orbitrap Fusion Lumos Tribrid Mass Spectrometer (Thermo Scientific), respectively, coupled to a Dionex UltiMate 3000 UHPLC system (Thermo Scientific) equipped with an in-house-packed C 18 column (ReproSil-Pur 120 C18-AQ, 1.9 µm pore size, 75 µm inner diameter, 30 cm length, Dr. Maisch GmbH). Samples were separated applying the following 58 min gradient: mobile phase A consisted of 0.1% formic acid (v/v), mobile phase B of 80% acetonitrile/0.08% formic acid (v/v). The gradient started at 5% B, increasing to 8% B on Fusion and 15% on Fusion Lumos, respectively, within 3 min, followed by 8-42% B and 15-46% B within 43 min accordingly, then keeping B constant at 90% for 6 min. After each gradient the column was again equilibrated to 5% B for 6 min. The flow rate was set to 300 nl min −1 . MS1 spectra were acquired with a resolution of 120,000 in the Orbitrap covering a mass range of 380-1580 m/z. Injection time was set to 60 ms and automatic gain control target to 5 × 10 5 . Dynamic exclusion covered 10 s. Only precursors with a charge state of 3-8 were included. MS2 spectra were recorded with a resolution of 30,000 in the Orbitrap, injection time was set to 128 ms, automatic gain control target to 5 × 10 4 and the isolation window to 1.6 m/z. Fragmentation was enforced by higher-energy collisional dissociation at 30%.
Raw files were converted to mgf format using ProteomeDiscoverer 1.4 (Thermo Scientific, signal-to-noise ratio 1.5, 1,000-10,000 Da precursor mass). For identification of crosslinked peptides, files were analysed by pLink (v. 1.23), pFind group 87 using BS3 as crosslinker and trypsin as digestion enzyme with maximal two missed cleavage sites. Carbamidomethylation of cysteines was set as a fixed modification, oxidation of methionines as a variable modification. Searches were conducted in combinatorial mode with a precursor mass tolerance of 5 Da and a fragment ion mass tolerance of 20 p.p.m. The used database contained all proteins within the complex. The false discovery rate was set to 0.01. Results were filtered by applying a precursor mass accuracy of ±10 p.p.m. Spectra of both technical duplicates were combined and evaluated manually. Crosslinking figures were made with XiNet 88 and the Xlink Analyzer plugin in Chimera 89 . Distances between structured regions were calculated with Xlink Analyzer version 1.1.
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Kinase assays. A modified ATP/NADH coupled ATPase assay was used to measure relative rates of ATP hydrolysis of wild-type P-TEFb and D149N P-TEFb 90 . P-TEFb was titrated from 0-1 µM in a final solution containing 3 mM MgCl 2, 0.1 mM NADH, 0.4% (w/v) pyruvate kinase/lactate dehydrogenase, 1 mM phosphoenolpyruvate, 4 µM GST-RPB1 1593-1970, 100 mM NaCl, 20 mM Na-HEPES pH 7.4, 4% (v/v) glycerol and 1 mM DTT. Samples (50 µl, final volume) were incubated for 2 min at 30 °C before adding ATP (1 mM final concentration, pH 7.0). The decrease in absorption at 340 nm, corresponding to NADH oxidation, was measured in 384-well plates (Greiner Bio-One 384 well, clear flat bottom, 781101) over 60 min at 30 °C in a Tecan Infinite Pro M1000 plate reader. The rate of change in absorbance at 340 nm over time was determined from the linear region of the resulting absorbance curves. The experiment was performed three times and error bars represent the standard deviation between the three measurements.
Immunoblotting experiments were performed with GST-RPB1 1593-1970 and S. scrofa Pol II treated with wild-type P-TEFb or P-TEFb(D149N). GST-RPB1 1593-1970 (4 µM) was incubated with 100 nM wild-type P-TEFb or P-TEFb(D149N) in a final buffer containing 3 mM MgCl 2 , 100 mM NaCl, 20 mM Na-HEPES pH 7.4, 4% (v/v) glycerol, 1 mM ATP pH 7.5 and 1 mM DTT. The reactions were incubated at 30 °C and aliquots were taken at 0, 1, 5, 10, 15 and 30 min after ATP addition. Reactions were quenched by mixing 3 µl of sample with 12 µl of 4x LDS loading buffer (Invitrogen). Samples (2 µl) were run on 4-12% Bis-Tris gels in MES buffer (ThermoFisher Scientific). Proteins were transferred to nitrocellulose membranes (GE Healthcare Life Sciences) and were blocked with 5% (w/v) milk powder in PBS and 0.1% Tween 20 for 1-3 h at room temperature. The membranes were incubated with antibodies against Ser2 (3E8), Ser5 (3E10) (1:14 dilution, gift from D. Eick), and the CTD (MABI0601, MBL International Corporation, 1:1,000) overnight at 4 °C. Antibodies were diluted in 2.5% (w/v) milk in PBS with 0.1% Tween 20. Membranes were washed three times with PBS with 0.1% Tween 20. HRP-conjugated anti-rat secondary antibody (1:5,000) (Sigma-Aldrich A9037) was incubated with the membranes treated with Ser2 and Ser5 antibodies whereas the CTD membrane was treated with HRP conjugated anti-mouse antibody (1:3,000) (Abcam, ab5870) in PBS with 0.1% Tween 20 for 1 h at room temperature. SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher) was used for detection.
S. scrofa Pol II (2.4 µM) was treated with 0.4 µM wild-type P-TEFb for 1 h at 30 °C in a buffer containing 6 mM MgCl 2 , 3 mM ATP pH 7.0, and 1 Roche PhosStop tablet (Sigma-Aldrich) before size-exclusion chromatography. An aliquot of the peak fraction was used for immunoblotting. 0.5 µg of the protein was loaded on 4-12% Bis-Tris SDS-PAGE. Western blotting procedures are identical to those described for the GST-RPB1 CTD. Blots were performed using additional antibodies raised against phosphorylated Ser7 (4E12) and Tyr1 (3D12) (gift from D. Eick) as described above. Phosphorylation site mapping. NELF, PAF and SPT6 were treated with lambda protein phosphatase during purification to remove phosphorylations that were added by insect cells during protein expression. P-TEFb was incubated with individual factors or with elongation complexes containing PAF, SPT6 and DSIF before size-exclusion chromatography. Protein or fractions from gel-filtration chromatography were applied to NuPAGE 4-12% Bis-Tris SDS-PAGE gels (ThermoFisher Scientific) and stained with InstantBlue (Expedeon). Appropriate bands were selected for MS analysis.
Phosphopeptides derived after in-gel digest of the sample were enriched as described previously 91 . Enriched phosphopeptides were analysed on a LC-coupled Q-Exactive HF mass spectrometer (ThermoFisher Scientific) under standard chromatography conditions as described 91 . The MS raw files were processed by MaxQuant 92 (version 1.5.2.8) and MS/MS spectra were searched against Uniprot human database with Andromeda 93 search engine. Allowed variable modifications included phosphorylation of serine, threonine and tyrosine, methionine oxidation, and carbamidomethlyation of cysteine. Sites reported here were present in at least two biological replicates. 80% of the reported sites are found in Phosida 94 and PhosphoSitePlus 95 (with the following exceptions: SPT5 S148, S149, T153; SPT6 S1525; NELF-A S244 and all sites for CDC73 and PAF1). Five sites we detected were previously shown to be P-TEFb phosphorylation sites (NELF-E S181; NELF-A T277, S363; SPT5 666, 806) 10, 12, 42 . In vitro kinase assay and mapping of phosphorylation sites in the CTD linker. We were unable to detect P-TEFb specific phosphorylation sites in the linker from our initial MS experiments because the region is devoid of basic residues that are required for trypsination. The CTD linker has a high frequency of hydrophobic residues, which makes it amenable for chymotrypsin digestion. MBP RPB1 1488-1592 was incubated with wild-type P-TEFb or P-TEFb mutant D149N for 30 min at 30 °C under the following conditions: P-TEFb 1 µM, RPB1 1488-1592 36.5µM, 3 mM ATP pH 7.0, 6 mM MgCl 2 , 100 mM NaCl, 20 mM Na-HEPES pH 7.4, 4% (v/v) glycerol and 1 mM DTT. The assay was independently conducted twice.
Immediately after each in vitro phosphorylation reaction, proteins were precipitated using chloroform-methanol extraction as described 96 . Protein precipitates were resuspended in 50 mM ammonium bicarbonate containing 1% Rapigest surfactant (Waters), reduced with DTT and alkylated with iodoacetamide. Residual iodoacetamide was quenched with DTT. The Rapigest concentration was adjusted to 0.1% with 50 mM ammonium bicarbonate and CaCl 2 was added to a final concentration of 2 mM. Proteins were digested at a weight ratio of 75:1 with chymotrypsin (Roche) for 12 h at 25 °C 97 . The digest was then acidified and insoluble material was removed by centrifugation. The peptide mixture was desalted using self-made StageTips 98 containing Empore C18 solid phase extraction material (3M). Each sample was analysed in duplicate using an Orbitrap Fusion Lumos Tribrid mass spectrometer (ThermoFisher Scientific) coupled to a Dionex UltiMate 3000 nano liquid-chromatography system (ThermoFisher Scientific). Peptides were initially loaded onto a C18-trap column (0.3 × 5 mm, Dionex) in loading buffer (2% acetonitrile/0.05% TFA) and then separated on an analytical column (self-packed with 1.9 µm ReproSil-Pur C18-AQ material, 30 cm × 75 µm, Dr. Maisch) at flow rate of 300 nl min −1 using a 90 min multi-step gradient (2% acetonitrile/0.1% formic acid to 48% acetonitrile/0.1% formic acid).
The mass spectrometer was operated in a data-dependent mode to select from a MS survey scan (range: 350-1,550 m/z) the up to 20 most intense peptide precursors with charge states 2-7 for higher-energy collisional dissociation. Spectra were acquired in the Orbitrap at a resolution of 120,000 (MS1) and 30,000 (MS2) with automatic gain control target values of 6 × 10 5 (MS1) and 1.5 × 10 4 (MS2) respectively. A dynamic precursor exclusion of 10 s was used. MaxQuant 92 (version 1.5.2.8) equipped with the Andromeda search engine 93 was used to analyse the raw files against a database containing the recombinant protein sequences. Chymotrypsin was selected as protease with cleavage specificity for Trp, Tyr, Phe, Leu and Met. A maximum of two missed cleavage sites was allowed. Precursor and fragment ion tolerances during database search were 4.5 p.p.m. (after internal recalibration) and 20 p.p.m., respectively. Cysteine carbamidomethylation was set as static modification; serine, threonine and tyrosine phosphorylation, methionine oxidation and N-terminal protein acetylation were variable modifications. Label-free quantification was enabled. False discovery rates for peptide-spectrum matches and protein identifications were set to 1%. Phosphorylation sites were filtered for high confidence (P > 0.75), further examined manually and only considered relevant, when phosphorylated precursors were identified in both injection and assay replicates. Selected annotated MS2 spectra were exported as vector graphic using the MaxQuant Viewer and for better legibility labels were further modified in Adobe Illustrator CS6 (version 16.0.0).
Full sequence coverage for the RBP1-linker region and near-complete coverage (>88%) for MBP could be obtained for all replicates. Only non-phosphorylated MBP peptides were detected, confirming the specificity of the phosphorylation reaction. Phosphorylated CTD linker peptides were observed after incubation with wild-type P-TEFb (but not with D149N P-TEFb) and phosphorylation sites could be assigned with high confidence (post translational modification (PTM) score >0.98) to six different residues within the CTD linker (S1514, T1518, T1525, T1540, S1584 and S1590). We did not obtain direct evidence for phosphorylation of S1547, which was previously described to co-mediate SPT6 recruitment in yeast 44 , although we noted a considerable intensity decrease for the unphosphorylated counterpart peptide upon incubation with wild-type P-TEFb. Fluorescence anisotropy binding assays with CTD linker peptide. A 5,6-FAMlabelled peptide corresponding to human RPB1 residues 1521-1552 was purchased from Caslo ApS. The peptide was dissolved in 22% dimethylformamide to a concentration of 1 mM. The peptide (30 µM) was incubated with 1 µM wild-type P-TEFb or P-TEFb(D149N) in buffer containing 100 mM NaCl, 20 mM Na-HEPES pH 7.4, 4% (v/v) glycerol, 6 mM MgCl 2 , 3 mM ATP pH 7.0 and 1 mM DTT for 30 min at 30 °C. The reaction was quenched by addition of 10 mM EDTA pH 8.0.
The tSH2 was diluted in half-log steps in protein dilution buffer and mixed with diluted peptide on ice for 5 min. The reaction was diluted to achieve a final volume of 20 µl, final conditions: 10 nM peptide, 100 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol, 1 mM DTT, 1 mM EDTA pH 8.0. The reactions were incubated at room temperature for 20 min in the dark. 17 µl aliquots were removed and transferred to a Greiner 384-well black flat bottom small volume plate. Fluorescence anisotropy was measured at room temperature with an Infinite M1000 Pro plate reader (Tecan) with an excitation wavelength of 470 ± 5 nm, an emission wavelength of 518 ± 5 nm, and a gain of 75. The experiment was performed in triplicate and analysed with GraphPad Prism Version 6. Binding curves were fit using a single site quadratic binding equation as described 52 . Fluorescence anisotropy binding assays with SPT6 and nucleic acids. SPT6 was dialysed overnight against SPT6 FA buffer (150 mM NaCl, 20 mM Na-HEPES pH 7.4, 10% (v/v) glycerol and 1 mM DTT) in a 20 kDa MWCO Slide-A-Lyzer MINI Dialysis Unit. The protein was then used directly for anisotropy measurements. 25-mer 5′-/6-FAM labelled DNA and RNA oligonucleotides bearing the sequence AAG GGG AGC GGG GGA GGA TAA TAG G (T substituted with U in RNA sequence) were obtained from Integrated DNA Technologies and dissolved in water. SPT6 was serially diluted in half-log steps in SPT6 FA buffer. Nucleic acids (2.2 µl, 10 nM final concentration) and SPT6 (4.4 µl, 0-9.5 µM final concentration) were mixed on ice and incubated for 5 min. The assay was brought up to a final volume of 22 µl and incubated at room temperature in the dark for 20 min (final conditions: 30 mM NaCl, 3 mM MgCl 2 , 20 mM Na-HEPES pH 7.4, 50 µg ml BSA, 5 µg ml −1 yeast tRNA and 1 mM DTT). 18 µl of each solution was transferred to a Greiner 384 Flat Bottom Black Small volume plate. Fluorescence anisotropy was measured and analysed as above but with a gain of 70 and an emission wavelength of 518 ± 20 nm. Pull-down experiments. MBP-RPB1 1488-1970 and MBP RPB1 1593-1970 (5 µM) were incubated with 0.4 µM wild-type or P-TEFb(D149N) mutant in pulldown buffer (100 mM NaCl, 20 mM Na-HEPES pH 7.4, 4% (v/v) glycerol, 1 mM DTT and 3 mM MgCl 2 ) for 30 min at 30 °C. The CTD constructs were incubated with amylose beads for 10 min further. The beads were washed three times with pulldown buffer to remove P-TEFb and ATP. Full-length SPT6 or SPT6∆tSH2 were then added at a final concentration of 7.5 µM. The reactions were incubated at 30 °C for 15 min and washed three times with pulldown buffer. The MBP tag was eluted from the beads by applying pulldown buffer with 116 mM maltose to the beads. 20 µl of the eluted sample was applied to a 4-12% SDS-PAGE and stained with Coomassie blue. Crystal structure determination of SPT6 tSH2 domain. Frozen tSH2 protein was thawed and applied to a Superdex S200 increase 10/300 column equilibrated in SE buffer. Peak fractions were pooled, concentrated, and dialysed into a buffer containing 100 mM NaCl, 20 mM HEPES pH 7.4, and 1 mM TCEP pH 7. Diffraction data were collected at beamline PXII of the Swiss Light Source at the Paul Scherrer Institute 99 . The native dataset was collected at a wavelength of 0.999 Å. Diffraction images were processed with XDS 100 . The structure was solved with molecular replacement in Phaser 101 using a polyalanine model of the S. cerevisiae Spt6 tSH2 domain (PDB ID: 3PSJ). Refinement was performed using Phenix.Refine 102 applying riding hydrogens. The human tSH2 structure is nearly identical to the yeast structure except for an N-terminal loop that is involved in crystal packing and adopts an alternative conformation (Extended Data Fig. 8b ). The final model was refined to an R work /R free of 19.0%/22.3%. MolProbity 84 analysis showed that 98.61% of the residues reside in the most-favoured regions of the Ramachandran plot, and 1.39% fell in allowed regions. None of the residues fell in disallowed regions. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. The electron density reconstructions and the final EC* model were deposited with the Electron Microscopy Data Base (EMDB) under accession codes EMD-0030, EMD-0031, EMD-0032, EMD-0033, EMD-0034, EMD-0035, EMD-0036 and EMD-0037, and with the Protein Data Bank (PDB) under accession code 6GMH. The tSH2 domain model was deposited with the PDB under accession code 6GME. Source data for Figs. 1a and 5a, Extended Data Figs. 1a, e-k, m, 2a-j, l, m, 9a, and 10g-k are found in Supplementary Figs 1, 2 and Supplementary Table 8 .
